Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Inc.

Ardelyx ( ($ARDX) ) has provided an announcement. On April 16, 2026, Ardelyx’s board approved a second amendment to its Amended and Restated 2014 E...

Ardelyx Shareholders Approve Equity Plan Amendment and Directors

Ardelyx Inc ($ARDX) announced an update on their ongoing clinical study. This Phase 3 study, titled “A 26-Week, Multi-Center, Randomized, Double-Bl...

Current Quarter	$-0.02	Next Quarter	$0.04
Current Year	$-0.07	Next Year	$0.53
QoQ Growth	+300.0%	YoY Growth	+857.1%
3Y EPS CAGR	+14.8%	Target Price	$16.33
Consensus	Buy	Upside	+169.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARDX	$6.05	+3.60%	9.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARDX	$6.05	+3.6%	9.84M
3
4
5
6

ARDX

ARDX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ardelyx Inc. Data in Excel

Get Ardelyx Inc. Data in Excel